These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24220932)

  • 1. Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy.
    Ciomber A; Smagur A; Mitrus I; Cichoń T; Smolarczyk R; Sochanik A; Szala S; Jarosz M
    Arch Immunol Ther Exp (Warsz); 2014 Apr; 62(2):161-8. PubMed ID: 24220932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric protein ABRaA-VEGF121 is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16-F10 melanoma growth.
    Smagur A; Boyko MM; Biront NV; Cichoń T; Szala S
    Acta Biochim Pol; 2009; 56(1):115-24. PubMed ID: 19252752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.
    Jarosz-Biej M; Kamińska N; Matuszczak S; Cichoń T; Pamuła-Piłat J; Czapla J; Smolarczyk R; Skwarzyńska D; Kulik K; Szala S
    PLoS One; 2018; 13(1):e0191012. PubMed ID: 29320562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice.
    Jarosz-Biej M; Smolarczyk R; Cichoń T; Kułach N; Czapla J; Matuszczak S; Szala S
    Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):451-64. PubMed ID: 25801067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
    Yu Y; Huang R; Zong X; He X; Mo W
    BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model.
    Tang JC; Shen GB; Wang SM; Wan YS; Wei YQ
    Immunol Lett; 2014; 158(1-2):159-66. PubMed ID: 24406503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice.
    Hayata K; Iwahashi M; Ojima T; Katsuda M; Iida T; Nakamori M; Ueda K; Nakamura M; Miyazawa M; Tsuji T; Yamaue H
    PLoS One; 2013; 8(1):e53131. PubMed ID: 23372655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
    Ahn HM; Hong J; Yun CO
    Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
    Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
    Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.
    Zloza A; Dharmadhikari ND; Huelsmann EJ; Broucek JR; Hughes T; Kohlhapp FJ; Kaufman HL
    Cancer Immunol Immunother; 2017 Jan; 66(1):9-16. PubMed ID: 27757560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
    Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
    J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
    Tang Q; Jiang J; Liu J
    Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine A(2B) receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells.
    Kaji W; Tanaka S; Tsukimoto M; Kojima S
    J Toxicol Sci; 2014 Apr; 39(2):191-8. PubMed ID: 24646699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.
    Jarosz M; Jazowiecka-Rakus J; Cichoń T; Głowala-Kosińska M; Smolarczyk R; Smagur A; Malina S; Sochanik A; Szala S
    Gene Ther; 2013 Mar; 20(3):262-73. PubMed ID: 22495576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.